A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER® Device in Adult and Adolescent Patients With Persistent Asthma
- Conditions
- Asthma
- Interventions
- Drug: short acting β2-agonist
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 392
- Registration Number
- NCT00545272
- Locations
- 🇵🇱
Novartis Investigator site, Lubin, Poland
🇩🇪novartis Investigator site, Munchen, Germany
🇷🇺Novartis investigator site, Tomsk, Russian Federation
Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion Based Regimen in de Novo Living Donor Kidney Transplant Recipients
- Conditions
- Kidney Transplant
- First Posted Date
- 2007-10-02
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT00537862
- Locations
- 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of
To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB)
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT00537537
- Locations
- 🇮🇳
Novartis Investigative Site, Vellore, India
Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma
- First Posted Date
- 2007-09-27
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT00535951
- Locations
- 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Medical College of Georgia, Augusta, Georgia, United States
Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 35
- Registration Number
- NCT00535418
SD, IL-13 Production Rate in IPF
- First Posted Date
- 2007-09-20
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT00532233
- Locations
- 🇺🇸
Novartis Investigative Site, Pittsburgh, Pennsylvania, United States
Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.
- Conditions
- Multiple Myeloma
- Interventions
- Combination Product: Lenalidomide
- First Posted Date
- 2007-09-20
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 46
- Registration Number
- NCT00532675
- Locations
- 🇺🇸
UCSF Medical Center, San Francisco, California, United States
🇺🇸Emory University School of Medicine/Winship Cancer Institute Dept. of Winship Cancer Inst., Atlanta, Georgia, United States
🇪🇸Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain
Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma
- First Posted Date
- 2007-09-20
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT00532389
- Locations
- 🇺🇸
Innovative Medical Research of South Florida Dept.ofInnovativeMedResearch, Miami Shores, Florida, United States
🇺🇸Dana Farber Cancer Institute Clinical Research Coordinator, Boston, Massachusetts, United States
🇺🇸Hackensack University Medical Center Multiple Myeloma Division, Hackensack, New Jersey, United States
This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001A2307.
- Conditions
- Renal Transplantation
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 256
- Registration Number
- NCT00531440
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
This is a Two-year Follow-up Study to Evaluate the Long-term Safety, Tolerability and Efficacy of 2 Different Doses of Everolimus
- Conditions
- Renal Transplantation
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 237
- Registration Number
- NCT00531063
- Locations
- 🇨🇭
Novartis, Basel, Switzerland